

Sen. Ron Johnson: 5 Questions for FDA About Pfizer Vaccine Approval

By [Children's Health Defense](#)

Global Research, August 30, 2021

[Children's Health Defense](#) 27 August 2021

Region: [USA](#)

Theme: [Media Disinformation](#), [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at [@crg_globalresearch](#).

Sen. Ron Johnson (R-Wis.) on Thursday [sent a letter](#) to Dr. Janet Woodruff, acting commissioner of the U.S. Food and Drug Administration (FDA), demanding answers to five questions pertaining to the FDA's approval of the Pfizer Comirnaty COVID vaccine.

The FDA on Aug. 23 [granted full approval](#) to [Pfizer's](#) vaccine, over the objections of some scientists who pointed out that full approval was based on only six months' worth of data — despite clinical trials designed for two years — and that there was no public discussion of the data.

In his Aug. 26 letter, Johnson asked questions similar to [those raised](#) earlier this week by [Children's Health Defense](#) Chairman Robert F. Kennedy, Jr. and Dr. Meryl Nass about the legal distinction between the Pfizer-BioNTech vaccine being administered under [Emergency Use Authorization](#), and Pfizer's Comirnaty vaccine, which was granted full licensure.

In his letter, Johnson asks these five questions:

1. Why didn't the FDA grant full licensure for the Pfizer-BioNTech vaccine that is in use and available in the U.S.?
2. How are the Comirnaty and Pfizer-BioNTech COVID-19 vaccines “legally distinct” and what are the “certain differences”?
3. There is no doubt that the FDA's action will lead to more vaccine mandates and increased pressure on those currently choosing not to get vaccinated. Your letter to Pfizer suggests that “there is not sufficient approved vaccine available for distribution.” Is there sufficient supply in the U.S. of the Comirnaty vaccine to ensure that those being vaccinated under mandates will be receiving the FDA-approved version? Or is it more likely (or certain) that they will be vaccinated using the vaccine administered under the reissued EUA?
4. If there is insufficient supply of Comirnaty vaccines for those succumbing to the coercion of mandates, isn't the FDA de facto endorsing vaccine mandates utilizing EUA vaccines?

5. Will individuals who receive either vaccine be afforded the same legal protections if they are injured by the vaccine? If not, why not?

This isn't the first time Johnson has written the FDA about COVID vaccines. On Aug. 22, he sent a [letter](#) to Woodcock; Dr. Francis Collins, director of the National Institutes of Health (NIH); and Dr. Rochelle P. Walensky, director of Centers for Disease Control and Prevention, criticizing the FDA's decision not to hold a formal advisory committee meeting to discuss Pfizer's application for full approval of its vaccine.

In July, Johnson [held a news conference](#) with families injured by the vaccines, during which he said the medical community was "repeatedly ignoring" the vaccine-injured.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from CHD

The original source of this article is [Children's Health Defense](#)
Copyright © [Children's Health Defense](#), [Children's Health Defense](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Children's Health Defense](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca